Karuna Therapeutics surges 47% after Bristol Myers Squibb announces $14 billion deal
Bristol Myers Squibb said it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash.
Source link
Bristol Myers Squibb said it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash.
Source link